Development and Internal Validation of a Novel Prognostic Score in Metastatic Colorectal Cancer: A Comparative Retrospective Cohort Study with the Glasgow Prognostic Score and Gustave Roussy Immune Score

Background: Reliable prognostic stratification is essential in metastatic colorectal cancer (mCRC), yet current inflammation-based scores do not fully integrate systemic inflammation, tumor burden, and clinical characteristics. Objective: This study aimed to develop a novel prognostic score integrating clinical, tumor burden, and inflammatory parameters in patients with mCRC and to compare its performance with the Glasgow Prognostic Score (GPS) and Gustave Roussy Immune Score (GRIm). Materials and Methods: This retrospective single-center study included 310 patients with mCRC treated between 2015 and 2025. GPS and GRIm were calculated. The novel prognostic score was constructed using seven equally weighted prognostic variables encompassing clinical characteristics, tumor burden, and laboratory parameters. Survival analyses were performed using Kaplan–Meier and Cox regression. Model performance was assessed using AUC, reclassification, calibration, and decision curve analysis. Results: Most patients had ECOG PS 0–1 (96.1%), left-sided tumors (76.1%) and synchronous metastases (79.0%). The median follow-up was 23.6 months. Both GPS and GRIm were independent prognostic factors for OS. GPS demonstrated superior discriminative performance compared with GRIm (AUC for 24-month OS: 0.697 vs. 0.620; p = 0.005). The novel score stratified median OS into low-, intermediate-, and high-risk groups as 40.9, 25.4, and 11.5 months, respectively (p < 0.001). The novel model outperformed GPS and GRIm (AUC: 0.768) and improved reclassification. Bootstrap-based internal validation demonstrated low optimism and good calibration. Conclusions: The novel prognostic score integrating clinical, inflammatory, and tumor burden parameters demonstrated superior prognostic performance compared with GPS and GRIm in mCRC. This score may serve as tool for individualized risk stratification.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-06-29
DOI
https://doi.org/10.3390/jcm15135074
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and Internal Validation of a Novel Prognostic Score in Metastatic Colorectal Cancer: A Comparative Retrospective Cohort Study with the Glasgow Prognostic Score and Gustave Roussy Immune Score

Simay Çokgezer, Senem Karabulut
Journal of Clinical Medicine
Inflammatory Biomarkers in Disease Prognosis
article

Development and Internal Validation of a Novel Prognostic Score in Metastatic Colorectal Cancer: A Comparative Retrospective Cohort Study with the Glasgow Prognostic Score and Gustave Roussy Immune Score

Simay Çokgezer, Senem Karabulut
article en

Abstract

Background: Reliable prognostic stratification is essential in metastatic colorectal cancer (mCRC), yet current inflammation-based scores do not fully integrate systemic inflammation, tumor burden, and clinical characteristics. Objective: This study aimed to develop a novel prognostic score integrating clinical, tumor burden, and inflammatory parameters in patients with mCRC and to compare its performance with the Glasgow Prognostic Score (GPS) and Gustave Roussy Immune Score (GRIm). Materials and Methods: This retrospective single-center study included 310 patients with mCRC treated between 2015 and 2025. GPS and GRIm were calculated. The novel prognostic score was constructed using seven equally weighted prognostic variables encompassing clinical characteristics, tumor burden, and laboratory parameters. Survival analyses were performed using Kaplan–Meier and Cox regression. Model performance was assessed using AUC, reclassification, calibration, and decision curve analysis. Results: Most patients had ECOG PS 0–1 (96.1%), left-sided tumors (76.1%) and synchronous metastases (79.0%). The median follow-up was 23.6 months. Both GPS and GRIm were independent prognostic factors for OS. GPS demonstrated superior discriminative performance compared with GRIm (AUC for 24-month OS: 0.697 vs. 0.620; p = 0.005). The novel score stratified median OS into low-, intermediate-, and high-risk groups as 40.9, 25.4, and 11.5 months, respectively (p < 0.001). The novel model outperformed GPS and GRIm (AUC: 0.768) and improved reclassification. Bootstrap-based internal validation demonstrated low optimism and good calibration. Conclusions: The novel prognostic score integrating clinical, inflammatory, and tumor burden parameters demonstrated superior prognostic performance compared with GPS and GRIm in mCRC. This score may serve as tool for individualized risk stratification.

Journal of Clinical MedicineVol. 15(13)
Istanbul University (TR)
Reduced inequalities
Openalex Percentile: Top 8%
Inflammatory Biomarkers in Disease Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.